icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
Ugw8gx9gSd9Ne5CC
Listen
